日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study

阿贝西诺他（一种组蛋白去乙酰化酶抑制剂）治疗复发或难治性滤泡性淋巴瘤患者：一项多中心、单臂 II 期研究

期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-026-02646-z
Gui, Lin; Liu, Haifeng; Wang, Huaqing; Cao, Junning; Li, Yufu; Yu, Yong; Gao, Yuhuan; Li, Zhenling; Shen, Jianzhen; Zhang, Lei; Zhang, Qingyuan; Pan, Hongming; Zheng, Meifang; Ke, Xiaoyan; He, Hesheng; Guo, Shuangshuang; Wang, Yihao; Xu, Xiaohong; Zou, Liqun; Wu, Wentao; Shi, Yuankai
淋巴瘤
表观遗传
乙酰化
发表日期：2026
文献求助 收藏

Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

作者更正：Odronextamab 单药治疗复发/难治性弥漫性大 B 细胞淋巴瘤患者：ELM-2 II 期试验的主要疗效和安全性分析

期刊:Nature Cancer
影响因子:28.5
doi:10.1038/s43018-025-00967-6
Kim, Won Seog; Kim, Tae Min; Cho, Seok-Goo; Jarque, Isidro; Iskierka-Jażdżewska, Elżbieta; Poon, Li Mei; Prince, H Miles; Zhang, Huilai; Cao, Junning; Zhang, Mingzhi; Tessoulin, Benoît; Oh, Sung Yong; Lim, Francesca; Carpio, Cecilia; Tan, Tran-Der; Ayyappan, Sabarish; Gutierrez, Antonio; Cai, Jingxian; Ufkin, Melanie; Shariff, Saleem; Brouwer-Visser, Jurriaan; Chaudhry, Aafia; Mohamed, Hesham; Ambati, Srikanth; Walewski, Jan
细胞生物学
淋巴瘤
T细胞
发表日期：2025
文献求助 收藏

Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

Odronextamab单药治疗复发/难治性弥漫性大B细胞淋巴瘤患者：ELM-2 II期试验的主要疗效和安全性分析

期刊:Nature Cancer
影响因子:28.5
doi:10.1038/s43018-025-00921-6
Kim, Won Seog; Kim, Tae Min; Cho, Seok-Goo; Jarque, Isidro; Iskierka-Jażdżewska, Elżbieta; Poon, Li Mei; Prince, H Miles; Zhang, Huilai; Cao, Junning; Zhang, Mingzhi; Tessoulin, Benoît; Oh, Sung Yong; Lim, Francesca; Carpio, Cecilia; Tan, Tran-Der; Ayyappan, Sabarish; Gutierrez, Antonio; Cai, Jingxian; Ufkin, Melanie; Shariff, Saleem; Brouwer-Visser, Jurriaan; Chaudhry, Aafia; Mohamed, Hesham; Ambati, Srikanth; Walewski, Jan
B细胞
细胞生物学
淋巴瘤
免疫/内分泌
发表日期：2025
文献求助 收藏

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial

来那度胺联合R-CHOP方案（R2-CHOP）治疗新诊断的双表达弥漫性大B细胞淋巴瘤：一项前瞻性II期临床试验

期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-025-01229-5
Liu, Yizhen; Zhang, Qunling; Lv, Fangfang; Liu, Xiaojian; Ji, Dongmei; Xia, Zuguang; Jin, Jia; Tao, Rong; Zhang, Wenhao; Li, Xiaoqiu; Zhang, Shengjian; Wang, Zezhou; Wang, Jiachen; Hong, Xiaonan; Cao, Junning
B细胞
HOP
淋巴瘤
CHOP
细胞生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study

tazemetostat（一种 EZH2 抑制剂）治疗中国复发/难治性滤泡性淋巴瘤患者的疗效和安全性：一项多中心、单臂 II 期研究

期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2025.103399
Cao, Junning; Chen, Guangliang; Qiu, Lihua; Zhang, Liling; Jiang, Ming; Cheng, Ying; Zhang, Qiaohua; Liu, Lihong; Li, Ping; Shuang, Yuerong; Wang, Huaqing; Xue, Hongwei; Wu, Huijing; Zheng, Meifang; Zhou, Keshu; Li, Zhiming; Jing, Hongmei; Yang, Wei; Zhu, Zunmin; Li, Wenyu; Wangwu, Jiaxuan; Huang, Heyu; Jia, Qiantao; Chen, Dongmei; Fan, Songhua; Shi, M Ming; Su, Weiguo
淋巴瘤
EZH2
发表日期：2025
文献求助 收藏

Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma.

莫苏妥珠单抗在中国复发或难治性滤泡性淋巴瘤患者中的药代动力学和药效学的种族敏感性评估

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.70211
Li Junyi, Liao Michael Z, Wilkins Justin, Penuel Elicia, Wang Bei, Vadhavkar Shweta, Peng Kun, Cao Junning, Li Zhiming, Zhang Ye, Li Wenjin, Li Donghang, Zhou Mingzhu, Wei Michael C, Kwan Antonia, Zhao Rong, Li Chunze, Li Chi-Chung, Turner David C
肿瘤
淋巴瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial

依贝马来诺格司亭α，一种Fc融合蛋白，长效粒细胞集落刺激因子，用于降低化疗引起的粒细胞减少症风险：一项II期随机、多中心、开放标签试验的结果

期刊:Clinical Drug Investigation
影响因子:2.7
doi:10.1007/s40261-025-01479-y
Ji, Dongmei; Wang, Shufang; Yao, Wei; Hou, Denny; Wang, Xiaoyan; Ye, Changsheng; Li, Hongsheng; Yang, Hongjian; Yi, Jilin; Lu, Jinsong; Wang, Haibo; Xu, Xiaohong; Cai, Dongyan; Liu, Xiaoan; Yan, Xi; Nie, Jianyun; Cui, Shude; Jiang, Hongchuan; Cao, Junning
细胞生物学
粒细胞
发表日期：2025
文献求助 收藏

Efficacy and safety of chiauranib in a combination therapy in platinum-resistant or refractory ovarian cancer: a multicenter, open-label, phase Ib and II study

奇奥拉尼联合疗法治疗铂类耐药或难治性卵巢癌的疗效和安全性：一项多中心、开放标签的 Ib 期和 II 期研究

期刊:Molecular Cancer
影响因子:33.9
doi:10.1186/s12943-024-02076-x
Li, Jin; Liu, Jihong; Yin, Rutie; Zou, Dongling; Zheng, Hong; Cao, Junning; Chen, Zhendong; Sun, Wei; Gao, Yunong; Zhang, Songling; Zeng, Linjuan; An, Ruifang; Lu, Xianping; Ye, Shuang; Wu, Xiaohua
肿瘤
肿瘤免疫
卵巢癌
发表日期：2024
文献求助 收藏

Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors

Syk抑制剂sovleplenib治疗复发或难治性成熟B细胞肿瘤的I期研究

期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2022.282401
Song, Yuqin; Cao, Junning; Zhang, Qingyuan; Li, Caixia; Qiu, Lugui; Qi, Junyuan; Zhang, Huilai; Li, Wenyu; Liu, Lihong; Jing, Hongmei; Zhou, Keshu; Zhang, Weijing; Zhang, Liling; Li, Daqi; Zou, Liqun; Yang, Haiyan; Qian, Wenbin; Zhou, Hui; Hu, Jianda; Yin, Hongyan; Fu, Sisi; Fan, Songhua; Xu, Qian; Wang, Jian; Jia, Xiaoyun; Dai, Guangxiu; Su, Weiguo; Zhu, Jun
B细胞
肿瘤
肿瘤免疫
细胞生物学
免疫/内分泌
发表日期：2024
文献求助 收藏

Global research trends in the tumor microenvironment of hepatocellular carcinoma: insights based on bibliometric analysis

肝细胞癌肿瘤微环境的全球研究趋势：基于文献计量分析的见解

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2024.1474869
Han, Hongmin; Zhao, Ziyin; He, Mingyang; Guan, Ge; Cao, Junning; Li, Tianxiang; Han, Bing; Zhang, Bin
细胞生物学
肿瘤
肿瘤微环境
肿瘤免疫
发表日期：2024
文献求助 收藏